Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant Pharmaceuticals (VRX) PT Lifted to $271 at Cantor Fitzgerald
April 30, 2015 6:51 AM EDTCantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) price target of $271.00 (from $222.00) amid "strong" Q1 results.
Koffler commented, "Valeant reported revenues of $2.19B (+16% Y/Y) and adjusted non-GAAP EPS of $2.36 in 1Q:15 vs. guidance of 10-15% organic revenue growth and >$2.30 and FactSet consensus of... More
Valeant Pharmaceuticals (VRX) PT Lifted to $250 at Guggenheim Post Q1
April 29, 2015 10:16 AM EDTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) to $250.00 (from $210.00) following Q1 beat and better-than-expected 2016 outlook.
Chen commented, "The 1Q15 beat and better-than-expected outlook for '16+ support our positive thesis for... More
